RPL10L

Across TCGA pan-cancer cohorts, RPL10L Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPL10L data layer compared with 23 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher RPL10L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL10L expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

LGG, LUAD, and HNSC are the cancer types where RPL10L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.154	0.812	<.001	18	view →
LUAD	DFS	Median	IV	0.047	0.565	<.001	15	view →
HNSC	DFS	Median	IV	1.000	0.313	.032	10	view →
UCEC	OS	Median	All	0.965	0.650	.026	8	view →
PRAD	DFS	Median	All	0.617	0.886	.041	6	view →
LIHC	OS	Median	All	0.177	0.783	.003	6	view →
SKCM	DFS	Median	II,III,IV	0.988	0.665	.037	3	view →
LUSC	DFS	Median	All	1.000	0.740	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL10L–LGG (OS)

Open the LGG breakdown →